A new analysis published in BMJ Evidence-Based Medicine indicates that the opioid painkiller tramadol provides limited pain relief and is associated with an increased risk of adverse events, prompting experts to re-evaluate its use in treating chronic pain.
A new analysis published in BMJ Evidence-Based Medicine reveals that tramadol, a widely prescribed opioid painkiller, exhibits limited effectiveness and an increased risk of adverse effects . The study, which examined data from 19 randomized clinical trials involving 6,506 adults, casts doubt on the widespread use of tramadol for chronic pain management.
This opioid, often perceived as a safer alternative to more potent opioids, has historically been prescribed for conditions like osteoarthritis, chronic low back pain, neuropathic pain, and fibromyalgia. However, the analysis highlights that the pain relief provided by tramadol is minimal, falling short of what is generally considered clinically significant. Furthermore, the study underscores a heightened risk of both serious and non-serious adverse events, including cardiovascular issues. The researchers' findings suggest that the potential harms of tramadol may outweigh its benefits, particularly in the context of long-term use, although the trials themselves were often limited in duration. \The study compared tramadol to a placebo across various chronic pain conditions. While some pain reduction was observed, the effect was small. The study participants receiving tramadol experienced a higher incidence of adverse events compared to the placebo group. Serious adverse events included cardiovascular complications such as chest pain, coronary artery disease, and congestive heart failure, leading the authors to conclude that tramadol potentially increases the risk of heart-related issues. The analysis highlights that the benefits of tramadol for chronic pain are relatively modest and that the potential risks should be carefully considered. It's crucial to acknowledge that the majority of the trials included in the analysis were of relatively short duration, spanning from two to sixteen weeks of treatment, with follow-up periods ranging from three to fifteen weeks. This limited timeframe hindered the assessment of long-term outcomes and the full impact of tramadol on patients. The authors also noted that many outcomes had a high risk of bias, potentially inflating the perceived benefits and minimizing reported harms. Despite the study's findings, experts emphasize the importance of patients consulting with their healthcare providers before making any changes to their medication regimen, as abrupt discontinuation of tramadol can lead to withdrawal symptoms.\Several experts weighed in on the implications of the study. Dr. Marc Siegel, a senior medical analyst, pointed out the need to consider underlying patient characteristics and to differentiate tramadol from more potent opioids such as Percocet. He also cautioned against drawing definitive conclusions about the drug's impact on conditions like cancer or heart disease without controlling for other contributing factors and the absence of clear evidence of causation. Dr. Alopi M. Patel, a pain medicine physician, emphasized the importance of transparent shared decision-making between clinicians and patients, weighing the modest benefits of tramadol against its associated risks. The study's conclusions challenge the common practice of using tramadol for chronic pain, prompting a reevaluation of its risk-benefit profile. The limited pain relief offered by the drug, coupled with the increased risk of adverse events, particularly cardiovascular complications, suggests a cautious approach to its prescription and use. The findings also underscore the importance of shared decision-making between healthcare providers and patients when considering tramadol, highlighting the need for a thorough assessment of each individual's circumstances and potential risks
Tramadol Opioid Chronic Pain Cardiovascular Adverse Effects
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
We Found the Lululemon Belt Bag for Under $20—Shop It Now for a Limited TimeScore a viral belt bag for under $20, plus more editor- and shopper-favorite finds like Align leggings, Nulu flares, and ultra-soft pullovers specially priced.
Read more »
Lululemon Is a Good Fit for 2026: Limited Downside, Ample UpsideMarket Analysis by covering: Lululemon Athletica Inc. Read 's Market Analysis on Investing.com
Read more »
T.J. Watt limited in return to Steelers practiceSteelers edge rusher T.J.
Read more »
Tramadol's Effectiveness for Chronic Pain Questioned in New AnalysisA new analysis published in BMJ Evidence-Based Medicine suggests that the opioid painkiller tramadol has limited effectiveness and increases the risk of adverse effects for chronic pain. The study examined 19 clinical trials involving over 6,500 adults, finding a small reduction in pain and a higher risk of serious adverse events like cardiovascular issues. Experts emphasize the need for careful consideration of both the benefits and risks of tramadol and caution against abrupt discontinuation.
Read more »
Portillo’s partners with Bears wide receiver DJ Moore on limited-time mealChicago-based restaurant chain Portillo’s is partnering with Chicago Bears wide receiver DJ Moore on a new limited-time meal celebrating one of the team’s most memorable moments of the season.
Read more »
Tramadol's Effectiveness Questioned in New Analysis on Chronic PainA recent analysis published in BMJ Evidence-Based Medicine found that the opioid painkiller tramadol provides limited pain relief and may increase the risk of adverse events, particularly cardiovascular issues, in patients with chronic pain. Researchers analyzed data from 19 clinical trials, highlighting that the benefits of tramadol may not outweigh the risks. Experts emphasize that patients should consult with their doctors before making any changes to their medication.
Read more »